Daniel J. Czyzyk

Daniel J. Czyzyk

Auto-generated profile, based on publicly available information

Daniel J. Czyzyk

National Cancer Institute RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2025 in Science
Verified
Journal Article
Closed access
DSDhirendra K Simanshu
Dhirendra K Simanshu
RXRui Xu
Rui Xu
JSJames P. Stice
James P. Stice
DCDaniel J. Czyzyk
Daniel J. Czyzyk
SFSiyu Feng
Siyu Feng
PBPedro J. Beltran
Pedro J. Beltran
BBO-10203 is an orally available drug that covalently and specifically binds to the rat sarcoma (RAS)–binding domain of phosphoinositide 3-kinase α (PI3Kα), preventing its activation by HRAS, NRAS, and KRAS. It inhibited PI3Kα activation in tumors with oncogenic mutations in KRAS or PIK3CA and in tumors with human epidermal growth factor receptor 2 (HER2) amplification or overexpression. In preclinical models, BBO-10203 caused significant tumor growth inhibition across multiple tumor types and showed enhanced efficacy in combination with inhibitors of cyclin-dependent kinase 4/6 (CDK4/6), estrogen receptor (ER), HER2, and KRAS-G12C mutant, including in tumors harboring mutations in Kelch-like ECH-associated protein 1 (KEAP1) and serine/threonine kinase 11 (STK11). Notably, these antitumor effects occurred without inducing hyperglycemia, because insulin signaling does not depend on RAS-mediated PI3Kα activation to promote glucose uptake.

9 January 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DCDaniel Czyzyk
Daniel Czyzyk
WYWupeng Yan
Wupeng Yan
SMSimon Messing
Simon Messing
WGWilliam Gillette
William Gillette
TTTakashi Tsuji
Takashi Tsuji
DSDhirendra K Simanshu
Dhirendra K Simanshu
Mutations in RAS and PI3Kα are major drivers of human cancer. Their interaction plays a crucial role in activating PI3Kα and amplifying the PI3K-AKT-mTOR pathway. Disrupting RAS-PI3Kα interaction enhances survival in lung and skin cancer models and reduces tumor growth and angiogenesis, although the structural details of this interaction remain unclear. Here, we present structures of KRAS, RRAS2, and MRAS bound to the catalytic subunit (p110α) of PI3Kα, elucidating the interaction interfaces and local conformational changes upon complex formation. Structural and mutational analyses highlighted key residues in RAS and PI3Kα impacting binding affinity and revealed isoform-specific differences at the interaction interface in RAS and PI3K isoforms, providing a rationale for their differential affinities. Notably, in the RAS-p110α complex structures, RAS interaction with p110α is limited to the RAS-binding domain and does not involve the kinase domain. This study underscores the pivotal role of the RAS-PI3Kα interaction in PI3Kα activation and provides a blueprint for designing PI3Kα isoform-specific inhibitors to disrupt this interaction.

7 November 2011 in Biochemistry
Verified
Journal Article
Open access
DCDaniel J. Czyzyk
Daniel J. Czyzyk
CLCassie Liu
Cassie Liu
ETErika Taylor
Erika Taylor
Heptosyltransferase I (HepI) is responsible for the transfer of l-glycero-d-manno-heptose to a 3-deoxy-α-d-oct-2-ulopyranosonic acid (Kdo) of the growing core region of lipopolysaccharide (LPS). The catalytic efficiency of HepI with the fully deacylated analogue of Escherichia coli HepI LipidA is 12-fold greater than with the fully acylated substrate, with a kcat/Km of 2.7 × 106 M–1 s–1, compared to a value of 2.2 × 105 M–1 s–1 for the Kdo2-LipidA substrate. Not only is this is the first demonstration that an LPS biosynthetic enzyme is catalytically enhanced by the absence of lipids, this result has significant implications for downstream enzymes that are now thought to utilize deacylated substrates.

24 July 2025 in Science
Verified
Journal Article
Closed access
KTKoji Terayama
Koji Terayama
SFShinji Furuzono
Shinji Furuzono
NFNicole Fer
Nicole Fer
WYWupeng Yan
Wupeng Yan
LYLucy C. Young
Lucy C. Young
MFMcCormick Frank
McCormick Frank
While exploring strategies to control blood glucose concentrations in diabetes, we identified so-called molecular glues D223 and D927 that promote glucose uptake in the absence of insulin. They act by increasing the binding affinity of phosphoinositide 3-kinase α (PI3Kα) catalytic subunit p110α to canonical small guanosine triphosphatase RAS proteins and to RRAS, RRAS2, and MRAS by three orders of magnitude. The compounds bind to the RAS-binding domain of p110α, stabilizing the secondary structures of the PI3Kα in a RAS-binding conformation and forming direct interactions with RAS residues tyrosine-40 and arginine-41. In vivo, D927 mimicked the effects of insulin: It rapidly lowered blood glucose concentrations, enhanced glucose metabolism in normal and Zucker fatty rats, and improved hyperglycemia in models of type 1 and type 2 diabetes, even in insulin-deficient diabetic animals.

1 December 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DCD.J. Czyzyk
D.J. Czyzyk
MVM. Valhondo
M. Valhondo
LDL. Deiana
L. Deiana
JTJ. Tirado-Rives
J. Tirado-Rives
WJW.L. Jorgensen
W.L. Jorgensen
KAKaren Anderson
Karen Anderson